Ausgabe 1/2018
Inhalt (19 Artikel)
Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes
Ursula M. Vogl
In need of special care: adolescent and young adult patients with cancer
Michael N. Dworzak
Anti-angiogenic therapies in brain metastases
Anna S. Berghoff, Matthias Preusser
Antiangiogenic therapies in ovarian cancer
Adriaan Vanderstichele, Siel Olbrecht, Ignace Vergote
My burning issues in the neoadjuvant treatment for breast cancer
Elisabeth S. Bergen, Rupert Bartsch
Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer
Peter Horak
Local therapy of stage IV renal cell cancer: a case report
Muna Ferner, Andrea Vera Keck, Dora Niedersüß-Beke, Kathrin Strasser-Weippl
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients
Irene Resch, Shahrokh F. Shariat, Kilian M. Gust
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia
Mirella Ampatzidou, Charikleia Kelaidi, Michael N. Dworzak, Sophia Polychronopoulou
Short overview on the current standard of treatment in newly diagnosed multiple myeloma
Ella Willenbacher, Agnes Balog, Wolfgang Willenbacher
Cell free nucleic acids as diagnostic and prognostic marker in leukemia
Maryam Eini, Seyed Ali Nojoumi, Mohammad-Amin Saki, Abbas Khosravi
Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity
Malik Ghannam, Maria Bryan, Erik Kuross, Brent Berry
ESMO 2017—my personal highlights
Barbara Kiesewetter, Mircea Dediu, Rupert Bartsch